ArticleOphthalmology science2022
Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.
Michael J Allingham et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this papercites it